Prime Medicine posts corporate deck outlining prime editing pipeline focus on Wilson disease, AATD

Prime Medicine, Inc.

Prime Medicine, Inc.

PRME

0.00
  • Prime Medicine outlined a near-term push to advance prime-editing programs in Wilson disease and alpha-1 antitrypsin deficiency.
  • Targeted PM577 IND and/or CTA filing in H1 2026, followed by Phase 1 start; initial clinical data expected in 2027.
  • Planned PM647 IND and/or CTA filing mid-2026, followed by Phase 1 start; initial clinical data expected in 2027.
  • CGD program PM359 positioned toward a BLA filing, with a commercial launch targeted for 2027+.
  • Strategy includes additional partnerships, expansion beyond liver, with in vivo cystic fibrosis proof-of-concept data planned in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.